Combination of Intratumoral Invariant Natural Killer T Cells and Interferon-Gamma Is Associated with Prognosis of Hepatocellular Carcinoma after Curative Resection

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Xiao, Yong Sheng ^a,b   Gao, Qiang ^a,b   Xu, Xiang Nan ^a,b   Li, Yi Wei ^a,b   Ju, Min Jie ^a,b   Cai, Ming Yan ^a,b   Dai, Chen Xin ^a,b   Hu, Jie ^a,b   Qiu, Shuang Jian ^a,b   Zhou, Jian ^a,b   Fan, Jia ^a,b  

^a FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; GAMMA INTERFERON; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MESSENGER RNA; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR ALPHA VARIABLE 10; TATA BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL ENCAPSULATION; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER T CELL; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; HUMANS; INTERFERON-GAMMA; LIVER NEOPLASMS; NATURAL KILLER T-CELLS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84881188258     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070345     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Bruix J, Sherman M, (2010) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022.
3. Budhu A, Forgues M, Ye QH, Jia HL, He P, et al. (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99-111.
4. Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. (2007) Increased regulatory T cells correlated with CD8 T-cell impaired and poor survival in hepatocellular carcinoma. Gastroenterology 132: 2328-2339.
5. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, et al. (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593.
6. Sasaki A, Tanaka F, Mimori K, Inoue H, Kai S, et al. (2008) Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 34: 173-179.
7. Butterfield LH, (2007) Recent advances in immunotherapy for hepatocellular cancer. Swiss Med Wkly 137: 83-90.
8. Racanelli V, Rehermann B, (2006) The liver as an immunological organ. Hepatology 43: S54-S62.
9. Gao B, Jeong W, Tian Z, (2008) Liver: an organ with predominant innate immunity. Hepatology 47: 729-736.
10. Exley MA, Koziel MJ, (2004) To be or not to be NKT: natural killer T cells in the liver. Hepatology 40: 1033-1040.
11. Kronenberg M, (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 26: 877-900.
12. Seino K, Taniguchi M, (2005) Functionally distinct NKT cell subsets and subtypes. J Exp Med 202: 1623-1626.
13. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L, (2004) NKT cells: what's in a name? Nat Rev Immunol 4: 231-237.
14. Vijayanand P, Seumois G, Pickard C, Powell RM, Anqco G, et al. (2007) Invariant natural killer T cells in asthma and chronic obstructive pulmonary. N Engl J Med 356: 1410-1422.
15. Bendelac A, Savage PB, Teyton L, (2007) The biology of NKT cells. Annu Rev Immunol 25: 297-336.
16. Van Kaer L, (2007) NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 19: 1-11.
17. Brigl M, Brenner MB, (2004) CD1: antigen presentation and T cell function. Annu Rev Immunol 22: 817-890.
18. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H, (2003) The regulatory role of Va14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21: 483-513.
19. Terabe M, Berzofsky JA, (2007) NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol 28: 491-496.
20. Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, et al. (2007) Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25: 862-868.
21. Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, et al. (2005) Increased intratumor Valpha24-positive natural killer T cells: A prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11: 7322-7327.
22. Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi Z, et al. (2004) Natural killer T cells infiltrate neutoblastomas expressing the chemokine CCL2. J Exp Med 199; 1213-1221.
23. Notas G, Kisseleva T, Brenner D, (2009) NK and NKT cells in liver injury and fibrosis. Clin Immunol 130: 16-26.
24. Shibolet O, Alper R, Zlotogarov L, Thalenfeld B, Engelhardt D, et al. (2003) NKT and CD8 lymphocytes mediated suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer 106: 236-243.
25. Margalit M, Shibolet O, Klein A, Elinav E, Alper R, et al. (2005) Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes. Int J Cancer 115: 443-449.
26. Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, et al. (2003) CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer 106: 81-89.
27. Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, et al. (2009) Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol 182: 5140-5151.
28. Zigmond E, Shalev Z, Pappo O, Alper R, Zolotarov L, et al. (2008) NKT lymphocyte polarization determined by microenvironment signaling: a role for CD8+ lymphocytes and beta-glycosphingolipids. J Autoimmun 31: 188-195.
29. Budhu A, Wang XW, (2006) The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 80: 1197-1213.
30. Sobin LH, Wittekind C (2002) TNM classification of malignant tumors (ed 6). New York, NY, Wiley-Liss, PP 81-83.
31. Sun HC, Zhuang PY, Qin LX, Ye QH, Wang L, et al. (2007) Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 96: 37-45.
32. Ju MJ, Qiu SJ, Fan J, Xiao YS, Gao Q, et al. (2009) Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol 131: 498-510.
33. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, et al. (2009) Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15: 971-979.
34. Gao Q, Wang XY, Fan J, Qiu SJ, Zhou J, et al. (2008) Selection of reference genes for real-time PCR in human hepatocellular carcinoma tissues. J Cancer Res Clin Oncol 134: 979-986.
35. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 25: 402-408.
36. Camp RL, Dolled-Filhart M, Rimm DL, (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10: 7252-7259.
37. Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, et al. (2005) Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 242: 252-259.
38. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, et al. (2006) Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 243: 229-235.
39. Poon RT, Fan ST, Lo CM, Liu CL, Wong J, (2007) Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 245: 51-58.
40. Shah SA, Cleary SP, Wei AC, Yang J, Taylor BR, et al. (2007) Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 141: 330-339.
41. Cariani E, Pilli M, Zerbini A, Rota C, Olivani A, et al. (2012) Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS One 7: e32493.
42. Schoenborn JR, Wilson CB, (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96: 41-101.
43. Giaccone G, Punt CJ, Ando Y, Ruiiter R, Nishi N, et al. (2002) A phase I study of the natural killer T-cell ligand a-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8: 3702-3709.
44. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, et al. (2004) Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389.
45. Chang DH, Osman K, Connolly J, Kukreia A, Krasovsky J, et al. (2005) Sustained expansion of NKT cells and antigen-specificT cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503-1517.
46. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, et al. (2005) A phase I study of a-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910-1917.
47. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Izasa T, et al. (2006) A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12: 6079-6086.
48. Watarai H, Nakagawa R, Omori-Miyake M, Dashtsoodol N, Taniguchi M, (2008) Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat Protoc 3: 70-78.